Drug intelligence / Profile preview

WT-1-2.0

Development stage: Preclinical
Lead developer: Hangzhou Westan Pharmaceutical Technology
Modality: Small Molecules

Overview

WT-1-2.0 is a small molecule antagonist targeting the P2X3 receptor, currently in preclinical development by Hangzhou Westan Pharmaceutical Technology. The P2X3 receptor is a ligand-gated ion channel primarily expressed on sensory neurons and is known to play a critical role in the mediation of chronic pain and cough. By inhibiting P2X3, WT-1-2.0 aims to provide a therapeutic option for various pain conditions. The drug is currently undergoing druggability optimization to refine its pharmacological profile for further clinical advancement.

Targets

P2X3 (P2X purinoceptor 3)

Beyond the preview

Go deeper on WT-1-2.0.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WT-1-2.0.

Explore the full profile